PLIANT THERAPEUTICS INC (PLRX) Stock Income Statement
NASDAQ:PLRX - Nasdaq - US7291391057 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.58M | 9.69M | 7.57M | |||
| Operating Expenses | 234.91M | 228.37M | 185.72M | 136.89M | 105.11M | |||
| Research and Development | 175.60M | 169.31M | 127.80M | 96.94M | 77.55M | |||
| Selling, General, and Administrative Expenses | 59.31M | 59.05M | 57.93M | 39.95M | 27.56M | |||
| Operating Income | -234.91M | -228.37M | -184.15M | -127.20M | -97.54M | |||
| Interest Income/Expense | 15.39M | 18.06M | 22.81M | 3.88M | 270.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -219.51M | -210.30M | -161.34M | -123.32M | -97.26M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | -219.51M | -210.30M | -161.34M | -123.32M | -97.26M | |||
| EBITDA | -232.85M | -226.24M | -182.30M | -125.38M | -96.00M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.61 | -3.47 | -2.75 | -2.94 | -2.71 | |||
| Non GAAP EPS | -3.61 | -3.47 | -2.76 | -2.97 | -2.71 | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | -10211.14% | -1272.65% | -1284.81% | |||
| Operating Profit Margin | N/A | N/A | -11654.75% | -1312.69% | -1288.51% | |||
All data in USD